SPHR PHR - ContraFect Corp VP HR
| CFRXDelisted Stock | USD 1.18 0.08 6.35% |
Insider
SPHR PHR is VP HR of ContraFect Corp
| Phone | 914 207 2300 |
| Web | https://www.contrafect.com |
ContraFect Corp Management Efficiency
The company has return on total asset (ROA) of (1.1744) % which means that it has lost $1.1744 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.0875) %, meaning that it created substantial loss on money invested by shareholders. ContraFect Corp's management efficiency ratios could be used to measure how well ContraFect Corp manages its routine affairs as well as how well it operates its assets and liabilities.ContraFect Corp currently holds 2.88 M in liabilities with Debt to Equity (D/E) ratio of 0.24, which may suggest the company is not taking enough advantage from borrowing. ContraFect Corp has a current ratio of 1.79, which is within standard range for the sector. Note, when we think about ContraFect Corp's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| David Hale | Dermata Therapeutics | 75 | |
| Professor MD | Allarity Therapeutics | 67 | |
| Waldemar Priebe | Cns Pharmaceuticals | N/A | |
| Ronald Dundore | Windtree Therapeutics | 69 | |
| CPA CTP | Cns Pharmaceuticals | 44 | |
| Robert McRae | Palisade Bio | N/A | |
| Steen Knudsen | Allarity Therapeutics | 63 | |
| John CPA | Unicycive Therapeutics | 62 | |
| Carol Odle | Revelation Biosciences | N/A | |
| Cameron Shaw | Virax Biolabs Group | 37 | |
| Gerald Proehl | Dermata Therapeutics | 65 | |
| Claus Pedersen | Allarity Therapeutics | 52 | |
| Frank Kondrad | Neurobo Pharmaceuticals | N/A | |
| Jason Davis | Virax Biolabs Group | 52 | |
| Gordon JD | Quoin Pharmaceuticals Ltd | 60 | |
| Sharon McBrayer | Palisade Bio | N/A | |
| Michael Myers | Quoin Pharmaceuticals Ltd | 62 | |
| MD FAAAAI | Palisade Bio | N/A | |
| James JD | Allarity Therapeutics | 55 | |
| PharmD BCPS | Neurobo Pharmaceuticals | N/A | |
| James Foster | Virax Biolabs Group | 39 | |
Management Performance
| Return On Equity | -6.09 | |||
| Return On Asset | -1.17 |
ContraFect Corp Leadership Team
Elected by the shareholders, the ContraFect Corp's board of directors comprises two types of representatives: ContraFect Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ContraFect. The board's role is to monitor ContraFect Corp's management team and ensure that shareholders' interests are well served. ContraFect Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ContraFect Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Chief Officer | ||
| SPHR PHR, VP HR | ||
| Natalie JD, Corp Counsel | ||
| Gary Woodnutt, VP Devel | ||
| FACP FACP, CEO Chairman |
ContraFect Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ContraFect Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -6.09 | |||
| Return On Asset | -1.17 | |||
| Current Valuation | (2.32 M) | |||
| Shares Outstanding | 10.7 M | |||
| Shares Owned By Insiders | 0.65 % | |||
| Shares Owned By Institutions | 6.13 % | |||
| Number Of Shares Shorted | 115.97 K | |||
| Price To Earning | 21.36 X | |||
| Price To Book | 0.44 X | |||
| Gross Profit | (1.61 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Other Consideration for investing in ContraFect Stock
If you are still planning to invest in ContraFect Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ContraFect Corp's history and understand the potential risks before investing.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |